Brazil’s healthcare market is in the grip of post-pandemic consolidation. The bet is that the race will end with four dominant groups.
Rede D’Or, the country’s largest private hospital chain, tightened its alliance with Bradesco Saúde by moving Glória D’Or into their 50-50 joint venture, Atlântica D’Or. The deal rekindles speculation of a broader merger, potentially including Fleury, where Bradesco is already a shareholder.
Hapvida is pushing ahead: it plans to invest R$2 billion ($370 million) by 2026 — half in São Paulo — to strengthen its vertical model. Amil, now under José Seripieri Filho, is eyeing new fronts with Dasa and even sniffing around UnitedHealth assets abroad. Meanwhile, the Unimed cooperative system, with more than 300 units and 16 million beneficiaries, remains a powerful regional force.
This is the front-running pack. But consumers face limits: healthcare costs surged after the pandemic, while the public SUS system remains a universal fallback. Insurers, meanwhile, are back to gorging on fat margins. In the first half of 2025, they posted operating profits of R$6.3 billion ($1.2 billion) — up 157% on the year — and net income of R$12.4 billion ($2.3 billion), a 143% jump. Regulation is weak. ANS, the industry watchdog, is unlikely to have the muscle to curb abuses or police megamergers.
Consolidation is the prescribed treatment. The danger is that the cure leaves patients — and investors — with an even heavier bill.
Leave a Reply